HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US OTC Market In 2020: COVID-19 Impact Obvious In Medical Device As Well As Drug Sales Growth

Executive Summary

Most notably among OTC drugs, hand sanitizer sales were up more than 600% to $1.46bn, while sales of consumer medical devices grew 15.6% to $14.8bn in 2020, according to CHPA report.

You may also be interested in...



US Seizes More Contaminated OTC Sanitizers From Mexico, Plus Subpotent Product From China

FDA also finding subpotent sanitizers made in China, according to warning letters submitted between 26 January and 5 February. Six recently warned firms began providing OTC sanitizers for distribution in the US after FDA in March temporarily loosened manufacturing standards.

Seeing Light At End Of Pandemic Tunnel, Prestige Consumer Healthcare Raises Earnings Guidance

Prestige Consumer Healthcare prepares to “lap the effects” of COVID-19 disruption on, estimating its fiscal year 2021 sales will reach $935m, ahead of earlier projections, and maintaining long-term organic growth targets of 2%-3%.

CHPA Rebranding Reflects Growing Device Interests In Evolving Self-Care Market

The Consumer Healthcare Products Association’s rebranding initiative – its first in 20 years – aligns the group with today’s self-care marketplace where consumer medical devices play an increasingly prominent role. It also follows “landmark legislative achievements in 2020 that will further empower consumers to practice responsible self-care,” CHPA says.

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel